Despite approval being a few years away at the moment, some believe that Pharmasset’s Hepatitus C treatment will potentially be a very big seller. The drug will be tested in mid-level trials later this year. Following the news of the Johnson and Johnson deal being made, Pharmasset’s shares rose 8% even though they have no currently marketed products.
Pharmasset’s deal with Johnson and Johnson, as well as others with Bristol-Myers Squibb and Roche, are not giving away future sales, so Pharmasset will retain the profit for itself, allowing the company to grow and ultimately providing more jobs and funding for research and development.
Looking for a job in pharmaceuticals? Start by clicking here now